Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q54535464)
Watch
English
Dual inhibition of HER2 in breast cancer treatment.
scientific article published on 17 January 2012
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
title
Dual inhibition of HER2 in breast cancer treatment.
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
author
Michael Gnant
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
author name string
Guenther G Steger
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
language of work or name
English
0 references
publication date
17 January 2012
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
volume
379
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
issue
9816
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
page(s)
596-598
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
cites work
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fighting overtreatment in adjuvant breast cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(12)60068-3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
PubMed publication ID
22257672
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22257672
retrieved
31 May 2018
reference URL
http://europepmc.org/abstract/MED/22257672
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit